Abstract PR011: Real-world efficacy of immune checkpoint inhibitors when used in a selected population of pediatric solid cancers – A retrospective multicenter study
The use of comprehensive molecular profiling to identify patients most likely to benefit from immunotherapy and warrant validation in prospective clinical trials is supported, and encouraging clinical activity in selected CAYAs with solid tumors when guided by tumor-specific biomarkers is demonstrated.